안과 의약품 시장

Ophthalmic Drugs Market- Scope of Report

TMR's report on the global Ophthalmic Drugs Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Ophthalmic Drugs Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ophthalmic Drugs Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Ophthalmic Drugs Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ophthalmic Drugs Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ophthalmic Drugs Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Ophthalmic Drugs Market .

The report delves into the competitive landscape of the global Ophthalmic Drugs Market . Key players operating in the global Ophthalmic Drugs Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ophthalmic Drugs Marketprofiled in this report.

Key Questions Answered in Global Ophthalmic Drugs MarketReport:

• What are the opportunities in the global Ophthalmic Drugs Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Ophthalmic Drugs Market- Research Objectives and Research Approach

The comprehensive report on the global Ophthalmic Drugs Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Ophthalmic Drugs Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Ophthalmic Drugs Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Ophthalmic Drugs Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure across Key Regions / Countries
• 5.2. Recent Advancements in Ophthalmic Medications
• 5.3. Epidemiology of Ophthalmic Disorders across Key Regions / Countries
• 5.4. Pricing Trends for Ophthalmic Drugs
• 5.5. Regulatory Scenario across Key Regions / Countries
• 5.6. PORTER's Five Forces Analysis
• 5.7. PESTEL Analysis
• 5.8. Value Chain Analysis
• 5.9. Key Purchase Metrics for End-users
• 5.10. Go-to-Market Strategy for New Market Entrants
• 5.11. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
• 5.12. Benchmarking of Key Products Offered by the Leading Competitors

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 6.3.1. Anti-Allergy Drugs
  • 6.3.2. Anti-infective Drugs
  • 6.3.3. Nonsteroidal Drugs
  • 6.3.4. Anti-VEGF Drugs
    • 6.3.4.1. Aptamer
    • 6.3.4.2. Antibodies (mAb & Bispecific Antibody)
    • 6.3.4.3. Fusion Protein
  • 6.3.5. Gene Therapy Drugs
  • 6.3.6. Others
• 6.4. Market Attractiveness By Drug Type

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Route of Administration

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 7.3.1. Topical
  • 7.3.2. Intraocular
  • 7.3.3. Others
• 7.4. Market Attractiveness By Route of Administration

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Dosage Form

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Dosage Form, 2020 to 2035
  • 8.3.1. Gel
  • 8.3.2. Drop
  • 8.3.3. Ointment
  • 8.3.4. Suspension & Solutions
  • 8.3.5. Others
• 8.4. Market Attractiveness By Dosage Form

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Product Type, 2020 to 2035
  • 9.3.1. Prescription Drugs
  • 9.3.2. Over-the-Counter
• 9.4. Market Attractiveness By Product Type

10. Global Ophthalmic Drugs Market Analysis and Forecasts, By Indication

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Indication, 2020 to 2035
  • 10.3.1. Glaucoma
  • 10.3.2. Dry Eye Disease
  • 10.3.3. Age-Related Macular Degeneration
  • 10.3.4. Diabetic Retinopathy
  • 10.3.5. Pink Eye
  • 10.3.6. Cataracts
  • 10.3.7. Retinal Detachment
  • 10.3.8. Others
• 10.4. Market Attractiveness By Indication

11. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channel

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
• 11.4. Market Attractiveness By Distribution Channel

12. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region

• 12.1. Key Findings
• 12.2. Market Value Forecast By Region
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness By Region

13. North America Ophthalmic Drugs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 13.2.1. Anti-Allergy Drugs
  • 13.2.2. Anti-infective Drugs
  • 13.2.3. Nonsteroidal Drugs
  • 13.2.4. Anti-VEGF Drugs
    • 13.2.4.1. Aptamer
    • 13.2.4.2. Antibodies (mAb & Bispecific Antibody)
    • 13.2.4.3. Fusion Protein
  • 13.2.5. Gene Therapy Drugs
  • 13.2.6. Others
• 13.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 13.3.1. Topical
  • 13.3.2. Intraocular
  • 13.3.3. Others
• 13.4. Market Value Forecast By Dosage Form, 2020 to 2035
  • 13.4.1. Gel
  • 13.4.2. Drop
  • 13.4.3. Ointment
  • 13.4.4. Suspension & Solutions
  • 13.4.5. Others
• 13.5. Market Value Forecast By Product Type, 2020 to 2035
  • 13.5.1. Prescription Drugs
  • 13.5.2. Over-the-Counter
• 13.6. Market Value Forecast By Indication, 2020 to 2035
  • 13.6.1. Glaucoma
  • 13.6.2. Dry Eye Disease
  • 13.6.3. Age-Related Macular Degeneration
  • 13.6.4. Diabetic Retinopathy
  • 13.6.5. Pink Eye
  • 13.6.6. Cataracts
  • 13.6.7. Retinal Detachment
  • 13.6.8. Others
• 13.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 13.7.1. Hospital Pharmacies
  • 13.7.2. Retail Pharmacies
  • 13.7.3. Online Pharmacies
• 13.8. Market Value Forecast By Country , 2020 to 2035
  • 13.8.1. U.S.
  • 13.8.2. Canada
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Drug Type
  • 13.9.2. By Route of Administration
  • 13.9.3. By Dosage Form
  • 13.9.4. By Product Type
  • 13.9.5. By Indication
  • 13.9.6. By Distribution Channel
  • 13.9.7. By Country

14. Europe Ophthalmic Drugs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 14.2.1. Anti-Allergy Drugs
  • 14.2.2. Anti-infective Drugs
  • 14.2.3. Nonsteroidal Drugs
  • 14.2.4. Anti-VEGF Drugs
    • 14.2.4.1. Aptamer
    • 14.2.4.2. Antibodies (mAb & Bispecific Antibody)
    • 14.2.4.3. Fusion Protein
  • 14.2.5. Gene Therapy Drugs
  • 14.2.6. Others
• 14.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 14.3.1. Topical
  • 14.3.2. Intraocular
  • 14.3.3. Others
• 14.4. Market Value Forecast By Dosage Form, 2020 to 2035
  • 14.4.1. Gel
  • 14.4.2. Drop
  • 14.4.3. Ointment
  • 14.4.4. Suspension & Solutions
  • 14.4.5. Others
• 14.5. Market Value Forecast By Product Type, 2020 to 2035
  • 14.5.1. Prescription Drugs
  • 14.5.2. Over-the-Counter
• 14.6. Market Value Forecast By Indication, 2020 to 2035
  • 14.6.1. Glaucoma
  • 14.6.2. Dry Eye Disease
  • 14.6.3. Age-Related Macular Degeneration
  • 14.6.4. Diabetic Retinopathy
  • 14.6.5. Pink Eye
  • 14.6.6. Cataracts
  • 14.6.7. Retinal Detachment
  • 14.6.8. Others
• 14.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 14.7.1. Hospital Pharmacies
  • 14.7.2. Retail Pharmacies
  • 14.7.3. Online Pharmacies
• 14.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 14.8.1. Germany
  • 14.8.2. UK
  • 14.8.3. France
  • 14.8.4. Italy
  • 14.8.5. Spain
  • 14.8.6. Switzerland
  • 14.8.7. The Netherlands
  • 14.8.8. Rest of Europe
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Drug Type
  • 14.9.2. By Route of Administration
  • 14.9.3. By Dosage Form
  • 14.9.4. By Product Type
  • 14.9.5. By Indication
  • 14.9.6. By Distribution Channel
  • 14.9.7. By Country / Sub-region

15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 15.2.1. Anti-Allergy Drugs
  • 15.2.2. Anti-infective Drugs
  • 15.2.3. Nonsteroidal Drugs
  • 15.2.4. Anti-VEGF Drugs
    • 15.2.4.1. Aptamer
    • 15.2.4.2. Antibodies (mAb & Bispecific Antibody)
    • 15.2.4.3. Fusion Protein
  • 15.2.5. Gene Therapy Drugs
  • 15.2.6. Others
• 15.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 15.3.1. Topical
  • 15.3.2. Intraocular
  • 15.3.3. Others
• 15.4. Market Value Forecast By Dosage Form, 2020 to 2035
  • 15.4.1. Gel
  • 15.4.2. Drop
  • 15.4.3. Ointment
  • 15.4.4. Suspension & Solutions
  • 15.4.5. Others
• 15.5. Market Value Forecast By Product Type, 2020 to 2035
  • 15.5.1. Prescription Drugs
  • 15.5.2. Over-the-Counter
• 15.6. Market Value Forecast By Indication, 2020 to 2035
  • 15.6.1. Glaucoma
  • 15.6.2. Dry Eye Disease
  • 15.6.3. Age-Related Macular Degeneration
  • 15.6.4. Diabetic Retinopathy
  • 15.6.5. Pink Eye
  • 15.6.6. Cataracts
  • 15.6.7. Retinal Detachment
  • 15.6.8. Others
• 15.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 15.7.1. Hospital Pharmacies
  • 15.7.2. Retail Pharmacies
  • 15.7.3. Online Pharmacies
• 15.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 15.8.1. China
  • 15.8.2. India
  • 15.8.3. Japan
  • 15.8.4. South Korea
  • 15.8.5. Australia & New Zealand
  • 15.8.6. Rest of Asia Pacific
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Drug Type
  • 15.9.2. By Route of Administration
  • 15.9.3. By Dosage Form
  • 15.9.4. By Product Type
  • 15.9.5. By Indication
  • 15.9.6. By Distribution Channel
  • 15.9.7. By Country / Sub-region

16. Latin America Ophthalmic Drugs Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 16.2.1. Anti-Allergy Drugs
  • 16.2.2. Anti-infective Drugs
  • 16.2.3. Nonsteroidal Drugs
  • 16.2.4. Anti-VEGF Drugs
    • 16.2.4.1. Aptamer
    • 16.2.4.2. Antibodies (mAb & Bispecific Antibody)
    • 16.2.4.3. Fusion Protein
  • 16.2.5. Gene Therapy Drugs
  • 16.2.6. Others
• 16.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 16.3.1. Topical
  • 16.3.2. Intraocular
  • 16.3.3. Others
• 16.4. Market Value Forecast By Dosage Form, 2020 to 2035
  • 16.4.1. Gel
  • 16.4.2. Drop
  • 16.4.3. Ointment
  • 16.4.4. Suspension & Solutions
  • 16.4.5. Others
• 16.5. Market Value Forecast By Product Type, 2020 to 2035
  • 16.5.1. Prescription Drugs
  • 16.5.2. Over-the-Counter
• 16.6. Market Value Forecast By Indication, 2020 to 2035
  • 16.6.1. Glaucoma
  • 16.6.2. Dry Eye Disease
  • 16.6.3. Age-Related Macular Degeneration
  • 16.6.4. Diabetic Retinopathy
  • 16.6.5. Pink Eye
  • 16.6.6. Cataracts
  • 16.6.7. Retinal Detachment
  • 16.6.8. Others
• 16.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 16.7.1. Hospital Pharmacies
  • 16.7.2. Retail Pharmacies
  • 16.7.3. Online Pharmacies
• 16.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 16.8.1. Brazil
  • 16.8.2. Mexico
  • 16.8.3. Argentina
  • 16.8.4. Rest of Latin America
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Drug Type
  • 16.9.2. By Route of Administration
  • 16.9.3. By Dosage Form
  • 16.9.4. By Product Type
  • 16.9.5. By Indication
  • 16.9.6. By Distribution Channel
  • 16.9.7. By Country / Sub-region

17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 17.2.1. Anti-Allergy Drugs
  • 17.2.2. Anti-infective Drugs
  • 17.2.3. Nonsteroidal Drugs
  • 17.2.4. Anti-VEGF Drugs
    • 17.2.4.1. Aptamer
    • 17.2.4.2. Antibodies (mAb & Bispecific Antibody)
    • 17.2.4.3. Fusion Protein
  • 17.2.5. Gene Therapy Drugs
  • 17.2.6. Others
• 17.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 17.3.1. Topical
  • 17.3.2. Intraocular
  • 17.3.3. Others
• 17.4. Market Value Forecast By Dosage Form, 2020 to 2035
  • 17.4.1. Gel
  • 17.4.2. Drop
  • 17.4.3. Ointment
  • 17.4.4. Suspension & Solutions
  • 17.4.5. Others
• 17.5. Market Value Forecast By Product Type, 2020 to 2035
  • 17.5.1. Prescription Drugs
  • 17.5.2. Over-the-Counter
• 17.6. Market Value Forecast By Indication, 2020 to 2035
  • 17.6.1. Glaucoma
  • 17.6.2. Dry Eye Disease
  • 17.6.3. Age-Related Macular Degeneration
  • 17.6.4. Diabetic Retinopathy
  • 17.6.5. Pink Eye
  • 17.6.6. Cataracts
  • 17.6.7. Retinal Detachment
  • 17.6.8. Others
• 17.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 17.7.1. Hospital Pharmacies
  • 17.7.2. Retail Pharmacies
  • 17.7.3. Online Pharmacies
• 17.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 17.8.1. GCC Countries
  • 17.8.2. South Africa
  • 17.8.3. Rest of Middle East & Africa
• 17.9. Market Attractiveness Analysis
  • 17.9.1. By Drug Type
  • 17.9.2. By Route of Administration
  • 17.9.3. By Dosage Form
  • 17.9.4. By Product Type
  • 17.9.5. By Indication
  • 17.9.6. By Distribution Channel
  • 17.9.7. By Country / Sub-region

18. Competition Landscape

• 18.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 18.2. Market Share Analysis By Company (2024)
• 18.3. Company Profiles
  • 18.3.1. Alcon Inc.
    • 18.3.1.1. Company Overview
    • 18.3.1.2. Financial Overview
    • 18.3.1.3. Product Portfolio
    • 18.3.1.4. Business Strategies
    • 18.3.1.5. Recent Developments
  • 18.3.2. Novartis AG
    • 18.3.2.1. Company Overview
    • 18.3.2.2. Financial Overview
    • 18.3.2.3. Product Portfolio
    • 18.3.2.4. Business Strategies
    • 18.3.2.5. Recent Developments
  • 18.3.3. Bausch + Lomb.
    • 18.3.3.1. Company Overview
    • 18.3.3.2. Financial Overview
    • 18.3.3.3. Product Portfolio
    • 18.3.3.4. Business Strategies
    • 18.3.3.5. Recent Developments
  • 18.3.4. Merck & Co., Inc.
    • 18.3.4.1. Company Overview
    • 18.3.4.2. Financial Overview
    • 18.3.4.3. Product Portfolio
    • 18.3.4.4. Business Strategies
    • 18.3.4.5. Recent Developments
  • 18.3.5. Regeneron Pharmaceuticals Inc.
    • 18.3.5.1. Company Overview
    • 18.3.5.2. Financial Overview
    • 18.3.5.3. Product Portfolio
    • 18.3.5.4. Business Strategies
    • 18.3.5.5. Recent Developments
  • 18.3.6. Coherus BioSciences, Inc.
    • 18.3.6.1. Company Overview
    • 18.3.6.2. Financial Overview
    • 18.3.6.3. Product Portfolio
    • 18.3.6.4. Business Strategies
    • 18.3.6.5. Recent Developments
  • 18.3.7. Pfizer Inc.
    • 18.3.7.1. Company Overview
    • 18.3.7.2. Financial Overview
    • 18.3.7.3. Product Portfolio
    • 18.3.7.4. Business Strategies
    • 18.3.7.5. Recent Developments
  • 18.3.8. AbbVie
    • 18.3.8.1. Company Overview
    • 18.3.8.2. Financial Overview
    • 18.3.8.3. Product Portfolio
    • 18.3.8.4. Business Strategies
    • 18.3.8.5. Recent Developments
  • 18.3.9. RIBOMIC
    • 18.3.9.1. Company Overview
    • 18.3.9.2. Financial Overview
    • 18.3.9.3. Product Portfolio
    • 18.3.9.4. Business Strategies
    • 18.3.9.5. Recent Developments
  • 18.3.10. Santen Pharmaceutical Co., Ltd.
    • 18.3.10.1. Company Overview
    • 18.3.10.2. Financial Overview
    • 18.3.10.3. Product Portfolio
    • 18.3.10.4. Business Strategies
    • 18.3.10.5. Recent Developments
  • 18.3.11. Cipla Limited
    • 18.3.11.1. Company Overview
    • 18.3.11.2. Financial Overview
    • 18.3.11.3. Product Portfolio
    • 18.3.11.4. Business Strategies
    • 18.3.11.5. Recent Developments
  • 18.3.12. Lupin Pharmaceuticals, Inc.
    • 18.3.12.1. Company Overview
    • 18.3.12.2. Financial Overview
    • 18.3.12.3. Product Portfolio
    • 18.3.12.4. Business Strategies
    • 18.3.12.5. Recent Developments
  • 18.3.13. Ocular Therapeutix, Inc.
    • 18.3.13.1. Company Overview
    • 18.3.13.2. Financial Overview
    • 18.3.13.3. Product Portfolio
    • 18.3.13.4. Business Strategies
    • 18.3.13.5. Recent Developments
  • 18.3.14. Novaliq GmbH
    • 18.3.14.1. Company Overview
    • 18.3.14.2. Financial Overview
    • 18.3.14.3. Product Portfolio
    • 18.3.14.4. Business Strategies
    • 18.3.14.5. Recent Developments
  • 18.3.15. ZEXUS PHARMA
    • 18.3.15.1. Company Overview
    • 18.3.15.2. Financial Overview
    • 18.3.15.3. Product Portfolio
    • 18.3.15.4. Business Strategies
    • 18.3.15.5. Recent Developments
  • 18.3.16. Grevis Pharmaceuticals Pvt. Ltd.
    • 18.3.16.1. Company Overview
    • 18.3.16.2. Financial Overview
    • 18.3.16.3. Product Portfolio
    • 18.3.16.4. Business Strategies
    • 18.3.16.5. Recent Developments